Sorrento Therapeutics Inc.

05/17/2022 | Press release | Distributed by Public on 05/17/2022 09:09

Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of[...]